Related Experiment Video

Updated: Mar 15, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?

A M Mohamed Thoufic Ali1, S Vino2

  • 1Department of Integrative Biology, School of Bio Sciences and Technology, VIT University, Vellore, Tamil Nadu, 632014, India.

Rheumatology International
|September 18, 2016
PubMed

Insights

Genetic and environmental factors influence rheumatoid arthritis (RA), a chronic autoimmune disease. Understanding genetic markers and their role in pathogenesis is key for early diagnosis and targeted RA therapies.

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is a complex autoimmune disease influenced by genetic and environmental factors.
  • While these factors are crucial, they are insufficient alone to cause RA, indicating intricate disease development pathways.
  • Genetic variations play a significant role in RA pathogenesis and can influence therapeutic responses.

Purpose of the Study:

  • To review the significance of genetic marker architecture in rheumatoid arthritis.
  • To explore the mechanisms of RA pathogenesis through genetic and functional studies.
  • To highlight the potential of novel gene discovery for biomarkers and treatment.

Main Methods:

  • Genome-wide association studies (GWAS) and meta-analyses to identify genetic RA markers.
  • Functional and genetic studies of individual RA-associated genes.
  • Review of current literature on genetic contributions to RA.

Main Results:

  • Identified key RA-associated genes including HLA-DRB1, HLA-DQB1, HLA-DPB1, PADI4, PTPN22, TRAF1-C5, STAT4, and C5orf30.
  • Demonstrated the interplay between genetic variations, gene expression, and RA pathogenesis.
  • Highlighted the ongoing need for comprehensive genetic profiling in RA.

Conclusions:

  • The genetic architecture of RA is complex and not yet fully elucidated.
  • Further post-genomic and functional genomic research is essential for a clearer understanding of RA's genetic basis.
  • Discovering novel RA-associated genes can lead to improved diagnostic biomarkers and more effective treatments.
Keywords:
C5orf30Early diagnosisGenetic markersRheumatoid arthritis

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients09:31

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients

Published on: October 16, 2016

10.0K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K